Overview

Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma

Status:
Completed

Trial end date:
2017-03-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.

Phase:

Phase 2

Details

Lead Sponsor:

MedImmune LLC

Collaborator:

Amgen